- PLN156.25m
- PLN135.49m
- PLN6.02m
Brief: Molecure To Regain Worldwide Rights To Dual Chitinase Inhibitor Oatd-01
Brief: Oncoarendi Therapeutics FY 2021 Net Result Turns To Loss Of 13.6 Mln Zlotys
Brief: Oncoarendi Therapeutics Signs Deal For Exclusive Licence Of Protein Inhibitors With University Of Michigan
Brief: Oncoarendi Therapeutics To Withdraw From In Consortium Deal With ABM
Brief: Oncoarendi Therapeutics Signs Deal With Biomapas For Clinical Study On OATD-02
Brief: Oncoarendi Therapeutics Appoints Samson Fung As Chief Medical Officer
Brief: Oncoarendi Therapeutics Changes Name To Molecure
Brief: WSE Says Pepco Group To Replace Oncoarendi Therapeutics On mWIG40 Index
Brief: Oncoarendi Therapeutics Gets Recommended For Subsidy Of About 37 Mln Zlotys
Brief: Oncoarendi Therapeutics Q3 Net Loss Widens To 1.9 Mln Zlotys
Brief: Poland's Oncoarendi Therapeutics H1 Net Loss Widens To 4.9 Mln Zlotys
Brief: OncoArendi Therapeutics Says Gets Polish Tax Office Interpretation On IP BOX
Brief: OncoArendi Therapeutics To Cooperate With Polish Institute On Small Molecule Drugs
Brief: Poland's Oncoarendi Therapeutics Q1 Net Loss Widens To 2.1 Mln Zlotys
Brief: OncoArendi Therapeutics FY Net Result Turns To Profit Of 64.3 Mln Zlotys
Brief: Oncoarendi Therapeutics Adopts Strategy For 2021-2025
Brief: Oncoarendi And Galapagos Enter Into Exclusive Collaboration On Chitinase Inhibitors In Fibrosis
Brief: Oncoarendi Therapeutics Signs Cooperation Deal Regarding R&D In Treatment Of Post-Covid-19 Complications
Brief: Oncoarendi Therapeutics Ends Clinical Stage Of Multiple Ascending Dose Of OATD-01